Oculis Holding AG reported Q1 2026 results highlighting progress in its late-stage ophthalmology trials. The company completed key patient visits in its Phase 3 DIAMOND trials for OCS-01, a potential first non-invasive eye drop for diabetic macular edema, with data expected in June 2026 and possible FDA submission in Q4. Licaminlimab's precision medicine trial for dry eye disease is actively recruiting, with results anticipated by year-end. Privosegtor advanced with FDA protocol agreement and PRIME designation in Europe for optic neuropathies. Oculis holds $277.6 million in cash and investments, supporting operations into the second half of 2029. These developments position Oculis to address large unmet needs in eye diseases with innovative treatments and significant market potential.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
